Tags

Type your tag names separated by a space and hit enter

[Role of neuraminidase inhibitors for the treatment of influenza A virus infections].
Pathol Biol (Paris). 2010 Apr; 58(2):e69-78.PB

Abstract

Oseltamivir and zanamivir are two neuraminidase inhibitors (NAIs) active on A and B influenza viruses. These analogues have been developed from the structure of sialic acid, the neuraminidase (NA) substrate. Resistance to NAIs have been detected. They are mainly associated to mutations located on the NA gene. The use of these antiviral drugs remains low in the context of seasonal flu, even the duration of symptoms can be reduced of one day if an antiviral treatment is started within 48 hours after disease onset. NAIs also present a significant effect when used in postexposition prophylaxis. Resistance, mainly to oseltamivir, have been detected but remained rare until the spontaneous emergence in 2007-2008 winter of a seasonal A(H1N1) variant resistant to this drug. NAIs are also interesting for the treatment of severe flu infections, specially those associated to A(H5N1). Finally, because of the pandemic A(H1N1)2009 virus, NAIs use has largely increased for prophylactic and therapeutic treatment of severe and non severe infections. This large use may be associated to an increased risk of selection of resistant viruses. Up to now, this phenomenon remains fortunately limited but has to be closely monitored.

Authors+Show Affiliations

Virologie et pathologie humaine, CNRS FRE 3011, université de Lyon, université Lyon-1, 7, rue Guillaume-Paradin, 69372 Lyon cedex 08, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

20303677

Citation

Ferraris, O, et al. "[Role of Neuraminidase Inhibitors for the Treatment of Influenza a Virus Infections]." Pathologie-biologie, vol. 58, no. 2, 2010, pp. e69-78.
Ferraris O, Escuret V, Bouscambert-Duchamp M, et al. [Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. Pathol Biol. 2010;58(2):e69-78.
Ferraris, O., Escuret, V., Bouscambert-Duchamp, M., Lina, B., & Morfin, F. (2010). [Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. Pathologie-biologie, 58(2), e69-78. https://doi.org/10.1016/j.patbio.2010.01.011
Ferraris O, et al. [Role of Neuraminidase Inhibitors for the Treatment of Influenza a Virus Infections]. Pathol Biol. 2010;58(2):e69-78. PubMed PMID: 20303677.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Role of neuraminidase inhibitors for the treatment of influenza A virus infections]. AU - Ferraris,O, AU - Escuret,V, AU - Bouscambert-Duchamp,M, AU - Lina,B, AU - Morfin,F, Y1 - 2010/03/19/ PY - 2010/01/21/received PY - 2010/01/26/accepted PY - 2010/3/23/entrez PY - 2010/3/23/pubmed PY - 2010/8/13/medline SP - e69 EP - 78 JF - Pathologie-biologie JO - Pathol. Biol. VL - 58 IS - 2 N2 - Oseltamivir and zanamivir are two neuraminidase inhibitors (NAIs) active on A and B influenza viruses. These analogues have been developed from the structure of sialic acid, the neuraminidase (NA) substrate. Resistance to NAIs have been detected. They are mainly associated to mutations located on the NA gene. The use of these antiviral drugs remains low in the context of seasonal flu, even the duration of symptoms can be reduced of one day if an antiviral treatment is started within 48 hours after disease onset. NAIs also present a significant effect when used in postexposition prophylaxis. Resistance, mainly to oseltamivir, have been detected but remained rare until the spontaneous emergence in 2007-2008 winter of a seasonal A(H1N1) variant resistant to this drug. NAIs are also interesting for the treatment of severe flu infections, specially those associated to A(H5N1). Finally, because of the pandemic A(H1N1)2009 virus, NAIs use has largely increased for prophylactic and therapeutic treatment of severe and non severe infections. This large use may be associated to an increased risk of selection of resistant viruses. Up to now, this phenomenon remains fortunately limited but has to be closely monitored. SN - 1768-3114 UR - https://www.unboundmedicine.com/medline/citation/20303677/[Role_of_neuraminidase_inhibitors_for_the_treatment_of_influenza_A_virus_infections]_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0369-8114(10)00032-5 DB - PRIME DP - Unbound Medicine ER -